Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · December 31, 2022

Nivolumab Plus Ipilimumab vs EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic HNSCC

Journal of Clinical Oncology


Additional Info

Journal of Clinical Oncology
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651
J. Clin. Oncol 2022 Dec 06;[EPub Ahead of Print], RI Haddad, K Harrington, M Tahara, RL Ferris, M Gillison, J Fayette, A Daste, P Koralewski, B Zurawski, M Taberna, NF Saba, M Mak, A Kawecki, G Girotto, MA Alvarez Avitia, C Even, JGR Toledo, A Guminski, U Müller-Richter, N Kiyota, M Roberts, TA Khan, K Miller-Moslin, L Wei, A Argiris

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading